This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript

Stock quotes in this article: DYAX

Thank you, Jen. Good evening everyone and welcome to Dyax Corp.’s second quarter 2012 earnings call. My remarks today will provide you with highlights on the second quarter, and a review of our key value drivers, KALBITOR angioedema franchise, as well as the Licensing and Funding Research Program.

We are pleased to report another strong quarter for our KALBITOR business, marking the ninth quarter in a row of steady, consistent revenue growth. This is based on solid execution of our strategy to provide patients with premiere services and support.

We will go into more detailed account of the KALBITOR business momentarily, but I want to mention a few key metrics and achievements we had this past quarter. First, KALBITOR sales for the second quarter were $9.2 million, up 14% from the first quarter of 2012. Second, patients treated with KALBITOR increased to 518, up 12% from the first quarter of 2012. This continued positive momentum is a result of delivering first class services and support to the entire HAE community, including patients, advocates and healthcare professionals.

We have launched several new programs in the last quarter, designed to identify and attract new patients, which together with our entire suite of offerings positions Dyax for continued growth in the KALBITOR business. Along with the developing the HAE market, we are also leveraging our knowledge of the plasma kallikrein pathway to ultimately diagnose and treat other angioedema states. Our second pillar, the LFRP, continues to be a near- and long-term value driver for Dyax. It already provides us with approximately $15 million in revenues annually, and has significant potential, through its broad and maturing pipeline of clinical candidates, addressing large therapeutic markets.

For more detail on these key business areas, I’ll now turn the call over to our executive management team. First, Rick Berard, Vice President, Commercial, will discuss our ongoing marketing efforts for KALBITOR in the U.S. Dr. Burt Adelman, Chief Medical Officer, will discuss our resurging initiatives in the angioedema franchise. Dr. Ivana Magovčević-Liebisch, Chief Business Officer, will discuss our global expansion efforts for KALBITOR, as well as the LFRP. And finally, George Miguasky, Chief Financial Officer, will present our financial highlights and financial guidance. Following these updates, I will provide concluding remarks, then open the lines for Q&A. At this time, I will turn the call over to Rick, who will review the progress of KALBITOR in the U.S.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs